Espoo, June 20th, 2024. Euformatics, a Finnish bioinformatics company that develops clinical genomic data analysis tools, announced that it has signed a new channel partnership with Bioportugal, a Portuguese supplier of solutions for hospitals and clinical laboratories. As part of the collaboration, Bioportugal and Euformatics plan to locally market NGS data analysis tools to help Portuguese medical geneticists and molecular pathologists diagnose patients effectively and based on high-quality NGS data.
The collaboration covers the full suite of Euformatics bioinformatics tools for NGS data analysis. The secondary analysis module takes care of the computational heavy lifting of read alignment and variant calling from the raw sequence data. The variants are then automatically transferred to the tertiary analysis module, which automates the process of annotation, classification, interpretation and reporting of clinically relevant variants. This clinical workflow is controlled by a comprehensive quality control module that calculates up to 60 quality metrics from the FASTQ, BAM and VCF files that the bioinformatics process produces. QC service includes a module for NGS test validation that the laboratory can use when introducing new tests to their portfolio and needing to validate the analytical performance of the pipeline.
José Belchior Nunes, President and CEO of Bioportugal, says, “Today marks our 34th anniversary. We have built a strong presence in the Portuguese healthcare market during the past decades and this announcement is a great way to celebrate this achievement. Euformatics tools for NGS data analysis nicely complement and complete our offering in molecular genetics and pathology. Clinical laboratories can now get the full end-to-end solution from consumables to bioinformatics from us, supported by a local team of field application specialists.”
Euformatics’ CEO, Tommi Kaasalainen continues, “We are very happy to sign Bioportugal as our local partner in Portugal. We have operated directly in the market with few customers for several years and now we get a nice boost to our presence through this partnership. There are nice synergies also here with Nonacus kits being represented by Bioportugal and us having worked with and validated Nonacus data on our platform in other markets already. Thus, Portuguese customers can feel confident that the end-to-end solution also works from beginning to end.“
This contract marks the 21st channel partnership agreement Euformatics has signed during the past few years, covering the Americas, Europe, the Middle East and Asia. Finding the best local partners continues to be one of the strategic priorities for the company.
About Bioportugal:
BIOPORTUGAL S.A. is a leading supplier of technological solutions to the hospital market, research centers, and laboratories, with a focus on Life Sciences and Laboratory Diagnosis. Founded in 1990, the company has established a strong presence in Portugal, with offices in Porto and Lisbon. With a global network of commercial partners from Europe, Asia, and North America, BIOPORTUGAL offers a wide range of products and services in areas such as pharmaceuticals, Life Sciences, Laboratory Diagnosis, and has a subsidiary in Spain, ELIGEN S.L., which operates in Life Sciences, Laboratory Diagnosis.
To learn more, visit https://www.bioportugal.pt/
About Euformatics:
Euformatics is a Finnish software company that specialises in high-standard bioinformatics tools for genomic data interpretation. Since 2010, Euformatics has been helping medical doctors and molecular genetics laboratories provide better precision medicine for cancer and common or rare disease diagnostics. At present, our core solution is the Genomics Hub which includes a variant interpretation tool; for clinical analysis and reporting of patient NGS data and a quality control tool; for NGS data quality management.
To learn more, visit www.euformatics.com
Press Relations:
Tommi Kaasalainen
Euformatics
tommi.kaasalainen@euformatics.com
